Skip to main content
AprilBio Co.,Ltd. logo

AprilBio Co.,Ltd. — Investor Relations & Filings

Ticker · 397030 ISIN · KR7397030008 KO Professional, scientific and technical activities
Open in API
Filings indexed 152 across all filing types
Latest filing 2026-05-15 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 397030

About AprilBio Co.,Ltd.

http://www.aprilbio.com/en/

AprilBio is a biotechnology company that develops innovative biologic drugs, including therapeutic antibodies and recombinant proteins. The company's core is its proprietary SAFA (anti-Serum Albumin Fab-Associated) platform technology, which utilizes an albumin-binding antibody fragment to create long-acting therapeutics. This platform is designed to enhance the efficacy, safety, and plasma half-life of drug candidates while minimizing adverse effects. AprilBio's research and development pipeline focuses on addressing unmet medical needs in therapeutic areas such as autoimmune diseases, oncology, and other inflammatory and rare diseases. The company advances new drug candidates through early clinical development stages for potential technology transfer.

Recent filings

Filing Released Lang Actions
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 99% confidence The document is titled “분기보고서” (Quarterly Report) covering the period 2026.01.01–2026.03.31, submitted to the Financial Services Commission and Korea Exchange. It contains detailed business description, financial data, real numbers for the quarter, and structured sections (company overview, business content, revenue, expenses, etc.). It is clearly an actual interim/quarterly report, not just an announcement or summary. Therefore it should be classified as an Interim/Quarterly Report. Q1 2026
2026-05-15 Korean
투자판단관련주요경영사항 (유한양행, SAFA 기반 융합단백질 기술라이선스 및 공동연구개발 계약 조기 종료)
Regulatory Filings Classification · 95% confidence The document is a short announcement (1161 characters) about the early termination of a technology license and joint research contract between two companies. It includes dates of occurrence and decision, details of the contract termination, and references a prior related announcement. There are no financial statements, detailed financial data, or comprehensive report content. The document is an update on a material event related to investment decisions, typical of a regulatory announcement rather than a full report or detailed filing. It fits best under Regulatory Filings (RNS) as a general regulatory announcement about a significant corporate event that does not fall into more specific categories like M&A or Capital Update.
2026-05-04 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 92% confidence The document is a Korean “임원·주요주주 특정증권등 소유상황보고서” (Form 6.1) reporting an executive’s and major shareholders’ holdings and changes in ownership of company stock. It details dates, share counts, ownership percentages, and acquisition events. This matches an insider share transaction report by company directors/executives, which corresponds to the “Director's Dealing” category (DIRS).
2026-04-16 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 91% confidence The document is a mandatory ‘‘임원ㆍ주요주주 특정증권등 소유상황보고서’’ (Report on the holding status of specific securities by executives and major shareholders) filed with the Korean Securities and Futures Commission and Korean Exchange. It details an executive’s insider shareholdings and transactions. This matches the insider/dealer reporting category rather than an earnings release or annual report. Therefore it is classified as Director’s Dealing (DIRS).
2026-04-16 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 85% confidence The document is a Korean "임원ㆍ주요주주 특정증권등 소유상황보고서" (Report on ownership status of specific securities by an officer or major shareholder), addressed to the Financial Supervisory Service and Korea Exchange. It details the insider’s shareholdings, acquisition/disposal dates, share counts, and percentages. This aligns with a Director’s Dealing filing, which reports personal transactions by company directors/executives. Therefore, the correct classification is DIRS.
2026-04-16 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 95% confidence The document is a Korean ‘주식등의 대량보유상황보고서(약식)’ filed with the Financial Services Commission and Korea Exchange, providing detailed disclosure of large shareholdings, threshold crossings, and changes in ownership percentages by a major shareholder. This matches the definition of a Major Shareholding Notification (MRQ).
2026-04-09 Korean

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.